Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership

We recently published 11 Best Cancer Stocks to Buy Right NowIncyte Corporation stands fourth on our list.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on cancer and inflammatory diseases, best known for Jakafi (ruxolitinib), a leading treatment for myelofibrosis and polycythemia vera. Its oncology portfolio also includes MONJUVI for lymphoma, PEMAZYRE for cholangiocarcinoma, ZYNYZ for Merkel cell carcinoma, and NIKTIMVO for chronic graft-versus-host disease, along with Opzelura for inflammatory skin conditions.

In Q2 2025, Jakafi delivered $764 million in revenue, an 8% year-over-year increase, prompting the company to raise full-year sales guidance to $3.0–3.05 billion. Strong demand and supportive healthcare policies have reinforced Jakafi’s growth, driving Incyte Corporation (NASDAQ:INCY)’s overall financial performance.

The business is expanding its precision medicine efforts through a global partnership with QIAGEN, developing a companion diagnostic for mutant calreticulin (mutCALR) to better identify patients for its investigational therapy INCA033989 in rare blood cancers.

Incyte Corporation (NASDAQ:INCY) reported positive Phase 2 results for povorcitinib, an oral JAK1 inhibitor for chronic spontaneous urticaria, underscoring diversification into immunology and dermatology. The corporation is also advancing a KRAS G12D inhibitor for pancreatic cancer, with potential as both a standalone and combination therapy.

Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership

A doctor examining a MRI scan and pointing to an image of a cancerous tumor.

Looking ahead, the firm expects 18+ clinical milestones in 2025, including four potential product launches, highlighting aggressive R&D investment across oncology and immune-related conditions.

While we acknowledge the risk and potential of INCY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INCY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.